Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study

Objective There is limited experience regarding the use of biological disease-modifying antirheumatic drug (bDMARD) and JAK inhibitor (JAKi) for the management of immune checkpoint inhibitors (ICI)-induced inflammatory arthritis. We aimed to assess their efficacy and safety in this setting.Methods U...

Full description

Bibliographic Details
Main Authors: Marie Kostine, Christophe Richez, Thierry Schaeverbeke, Gael Mouterde, Marie-Elise Truchetet, Julien Henry, Rakiba Belkhir, Vincent Germain, Isabelle Bonnet, Chi Duc Nguyen, Thao Pham, Claire Brière, Léa Rouxel, Thierry Cardon, Fanny De La Fuente, Pierre Edouard Gavand, Céline Labadie, Ambre Lauret
Format: Article
Language:English
Published: BMJ Publishing Group 2022-10-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/8/2/e002612.full

Internet

https://rmdopen.bmj.com/content/8/2/e002612.full

Similar Items